Physician profile
Patrick A Hotovy
NPI 1346296001
$2,459.98
in general payments reported to CMS, 2019-2025
25 companies · $40.24 in 2025
The $40.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $560 · 2021: $642 · 2022: $248 · 2023: $186 · 2024: $29.38 · 2025: $40.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.70 | 2020-2025 | |
| Allergan, INC. | $371.31 | 2019-2020 | |
| Novo Nordisk INC | $220.64 | 2019-2022 | |
| Amgen INC. | $214.16 | 2019-2022 | |
| Pfizer INC. | $166.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $153.45 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $132.21 | 2019-2021 | |
| Astellas Pharma US INC | $107.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.50 | 2021-2022 | |
| Daiichi Sankyo INC. | $26.41 | 2020-2021 | |
| Genentech USA, INC. | $25.44 | 2021-2022 | |
| Philips North America LLC | $24.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.37 | 2019-2020 | |
| Eisai INC. | $19.23 | 2020 | |
| Optinose US, INC. | $19.18 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17.97 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.72 | 2021 | |
| Merck Sharp & Dohme LLC | $16.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.25 | 2019 | |
| Acadia Pharmaceuticals INC | $14.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.11 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.03 | 2021 | |
| Biogen, INC. | $11.97 | 2021 | |
| Lilly USA, LLC | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hotovy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.